Albayda Jemima, Mammen Andrew L
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Curr Rheumatol Rep. 2014 Aug;16(8):433. doi: 10.1007/s11926-014-0433-8.
Statin medications have recently been shown to cause not only a toxic myopathy but also an immune-mediated necrotizing myositis. Before the discovery of a specific anti-HMG-CoA reductase antibody occurring in conjunction with a necrotizing myopathy, many of these patients may have been classified as polymyositis. They present similarly with proximal muscle weakness, elevated muscle enzymes, persistence of symptoms despite cessation of the statin, with need for immunosuppression. This article provides an overview of this novel disease entity by placing it in the context of existing idiopathic inflammatory myopathy (IIM) classification criteria, and in the range of statin-associated muscle toxicity.
他汀类药物最近被证明不仅会导致中毒性肌病，还会引发免疫介导的坏死性肌炎。在发现与坏死性肌病相关的特异性抗HMG-CoA还原酶抗体之前，许多这类患者可能被归类为多发性肌炎。他们的症状相似，表现为近端肌无力、肌肉酶升高、停用他汀类药物后症状仍持续存在，且需要免疫抑制治疗。本文通过将这种新型疾病实体置于现有的特发性炎性肌病（IIM）分类标准以及他汀类药物相关肌肉毒性范围内，对其进行了概述。
